Amido compounds and their use as pharmaceuticals

Patent metadata

Field	Value
Publication number	US-9957229-B2
Application number	US-201715602693-A
Country	US
Kind code	B2
Filing date	May 23, 2017
Priority date	May 7, 2004
Publication date	May 1, 2018
Grant date	May 1, 2018

Abstract

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

First claim

What is claimed is:

1. A compound, which is N-methyl-5-[4-(1-{[3-oxo-1′H,3H-spiro[2-benzofuran-1,3′-pyrrolidin]-1′-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide, wherein one or more hydrogen atoms are replaced by deuterium; or a pharmaceutically acceptable salt thereof.

2. A compound, which is N-methyl-5-[4-(1-{[(1R)-3-oxo-1′H,3H-spiro[2-benzofuran-1,3′-pyrrolidin]-1′-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide, wherein one or more hydrogen atoms are replaced by deuterium; or a pharmaceutically acceptable salt thereof.

3. A compound, which is N-methyl-5-[4-(1-{[(1R)-3-oxo-1′H,3H-spiro[2-benzofuran-1,3′-pyrrolidin]-1′-yl]carbonyl cyclopropyl)phenyl]pyridine-2-carboxamide, wherein one or more hydrogen atoms are replaced by deuterium.

4. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5. A pharmaceutical composition comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising the compound of claim 3 , and a pharmaceutically acceptable carrier.

Assignees

• Incyte Corp
• Incyte Holdings Corp

Inventors

• Yao Wenqing
• Zhuo Jincong
• Xu Meizhong
• Zhang Colin
• Metcalf Brian W
• He Chunhong
• Qian Ding-Quan

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title